AnalyzeDirect Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. June 2008;49(6):879-886.
Full Text – Open Access
Publication Date
June 2008
How Analyze was Used
“Image analysis was carried out using analysis software (Analyze Version 7 …) as previously reported [Kenny et al. 2005] to obtain time–activity curves.”
Keywords
Adult
Aged
Breast Neoplasms/metabolism/radionuclide imaging
Female
Humans
Metabolic Clearance Rate
Middle Aged
Oligopeptides/metabolism
Organ Specificity
Peptides/adverse effects/diagnostic use/pharmacokinetics
Polyethylene Glycols/adverse effects/diagnostic use/pharmacokinetics
Positron-Emission Tomography/adverse effects/methods
Radiopharmaceuticals/adverse effects/diagnostic use/pharmacokinetics
Tissue Distribution
Author Affiliation(s)
Department of Oncology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK. (LMK, RCC, KBC, CP, EOA)
GE Healthcare Medical Diagnostics, Amersham Place, Buckinghamshire, UK. (IO, MM, BP, PSC, AMH, SO, MG, DT)
Department of Nuclear Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK. (TJS, AAN)
ID# 1484
Tags: Adult, Aged, Breast Neoplasms/metabolism/radionuclide imaging, Female, Humans, Metabolic Clearance Rate, Middle Aged, Oligopeptides/metabolism, Organ Specificity, Peptides/adverse effects/diagnostic use/pharmacokinetics, Polyethylene Glycols/adverse effects/diagnostic use/pharmacokinetics, Positron-Emission Tomography (PET)/adverse effects/methods, Radiopharmaceuticals/adverse effects/diagnostic use/pharmacokinetics, Tissue Distribution